<DOC>
	<DOCNO>NCT01970020</DOCNO>
	<brief_summary>The purpose study investigate absorption , metabolism , excretion 14C JNJ-38518168 healthy adult male participant single oral dose 30 mg 14C JNJ-38518168 .</brief_summary>
	<brief_title>A Study Investigate Absorption , Metabolism , Excretion JNJ-38518168 After Single Oral Dose Healthy Male Participants .</brief_title>
	<detailed_description>This open-label ( people know identity intervention ) , single-center , single-arm ( single group ) , single-dose study . This study include screen period 21 day prior study medication administration . Six men enrol admitted clinical study unit morning Day -1 . On Day 1 , participant receive single oral solution dose contain 30 mg 14C JNJ-38518168 give oral solution . The participant confine clinical study unit least 360 hour dose ie , Day -1 Day 14 discharge Day 15 ; however , participant , Day 15 , meet discharge criterion extend residency study unit Day 21 . They return study center 7 10 day discharge final safety follow-up . The study include follow safety evaluation : adverse event , vital sign , 12-lead electrocardiography , physical examination , clinical laboratory test . For participant total duration study approximately 6 week ( include screen safety follow-up ) 7 week participant extend residence Day 21 .</detailed_description>
	<criteria>Healthy , male participant body mass index 18 30 kg/m2 ( inclusive ) body weight less 50 kg Must use adequate contraception donate sperm study 90 day receive study medication Nonsmoker blood pressure 90 140 mmHg systolic , inclusive , high 90 mmHg diastolic Have 12lead ECG consistent normal cardiac conduction function screen Exposure radiation professional medical reason past 12 month Recent change bowel habit ( frequency , consistency , amount ) irregular defecation pattern ( le one defecation per day ) History current clinically significant medical illness include ( limited ) cardiac arrhythmia cardiac disease , hematologic disease coagulation disorder History malignancy within 5 year screen Has receive Bacille CalmetteGu√©rin vaccination within 12 month live bacterial live viral vaccination within 12 week prior first administration study agent</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Healthy</keyword>
	<keyword>JNJ-38518168</keyword>
	<keyword>14C-JNJ-38518168</keyword>
	<keyword>Absorption</keyword>
	<keyword>Metabolism</keyword>
	<keyword>Excretion</keyword>
</DOC>